PET-MR Imaging with [18F]F-AraG for HIV Infection
Trial Summary
Do I need to stop my current medications for this trial?
The trial does not specify if you need to stop taking your current medications, but it mentions that participants who have not been on antiretroviral therapy (ART) for at least 1 week prior to the study can be enrolled. It is recommended to discuss your current medications with the study team.
Is [18F]F-AraG safe for use in humans?
How is the drug [18F]F-AraG different from other treatments for HIV?
What is the purpose of this trial?
This is a single center exploratory imaging study involving one intravenous microdose of \[18F\]F-AraG followed by whole-body positron emission tomography-magnetic resonance (PET-MR) imaging in HIV infected individuals to determine the anatomical distribution of the PET tracer. Participants will be enrolled if they were treated during early or late HIV infection. In addition, individuals not on antiretroviral therapy (ART) or with HIV-1 plasma RNA levels \>5,000 copies/mL will be enrolled. Up to 30 participants will be enrolled with HIV.
Research Team
Timothy J Henrich, MD
Principal Investigator
University of California, San Francisco
Eligibility Criteria
Adults over 18 with HIV, either treated early/late or not on antiretroviral therapy (ART), can join. They must understand the consent form and meet certain health criteria like a specific platelet count, liver enzyme levels, and kidney function. People with MRI contraindications, recent immune therapies, pregnancy/breastfeeding, transplants, severe infections or illnesses within 3 months are excluded.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Imaging
Participants receive one intravenous microdose of [18F]F-AraG followed by whole-body PET-MR imaging to determine the anatomical distribution of the PET tracer
Follow-up
Participants are monitored for any immediate reactions and to correlate [18F]F-AraG uptake with measures of HIV persistence
Treatment Details
Interventions
- [18F]F-AraG
Find a Clinic Near You
Who Is Running the Clinical Trial?
CellSight Technologies, Inc.
Lead Sponsor
University of California, San Francisco
Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator